Health Technology Assessment
Health Technology Assessment for Evidence-Based Healthcare Decision Making · Also known as: HTA, Technology Assessment Healthcare
Health Technology Assessment (HTA) is a structured, multidisciplinary approach to evaluating the clinical, economic, and societal effects of healthcare technologies (devices, drugs, procedures, systems). HTA synthesizes evidence from clinical trials, observational studies, and economic analyses to support decision-makers in adoption and reimbursement determinations.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Use HTA when evaluating high-cost technologies with significant budget impact, when clinical benefits are uncertain or modest, or when there are multiple competing alternatives. HTA is particularly valuable for medical devices, surgical procedures, diagnostic tests, and new drug formulations seeking reimbursement. Avoid HTA if the technology is well-established, comparator evidence is unavailable, or the decision timeline is too short to complete a rigorous assessment.
Strengths & limitations
- Comprehensive framework integrating clinical, economic, and social evidence into a single recommendation
- Transparent methodology allows stakeholders to understand how conclusions were reached
- Identifies evidence gaps, guiding future research priorities and conditions for coverage
- Applicable globally; can be adapted to different healthcare contexts and values
- Increasingly required by payers, regulatory agencies, and hospital systems for reimbursement decisions
- Time-intensive; a complete HTA typically requires 6–12 months or longer
- Quality of recommendations limited by quality of underlying clinical evidence; if trials are small or poorly designed, conclusions are uncertain
- Economic models require assumptions about clinical pathways, treatment discontinuation, and costs; results are sensitive to these assumptions
- Does not directly capture patient preferences and values; separate stakeholder engagement is needed
- Context-specific: recommendations valid in one healthcare system may not apply elsewhere due to differences in costs, practice patterns, and values
Frequently asked
What is the difference between HTA and economic evaluation?
Economic evaluation (cost-effectiveness analysis, cost-benefit analysis) quantifies the financial impact of a technology. HTA is broader: it integrates economic evaluation with clinical efficacy, safety, ethical, organizational, and social analyses. HTA uses economic evaluation as a component.
How do you quantify the clinical benefit in cost-per-QALY terms?
QALY (Quality-Adjusted Life Year) combines quantity and quality of life: a year in perfect health = 1 QALY, a year with significant disability = 0.5 QALY. A technology that extends life by 2 years but causes side effects resulting in 0.8 QALY per year = 1.6 QALYs gained. Cost per QALY is then total cost divided by QALYs gained.
What is considered a cost-effective threshold?
Different countries set different thresholds. The UK uses £20,000–30,000 per QALY, Australia uses AUD 50,000–65,000. The US typically uses USD 50,000–150,000 per QALY informally. Thresholds reflect values about health priorities and budget constraints; there is no universal standard.
What if there is not enough clinical evidence to perform an HTA?
Recommend conditional coverage: approve the technology under conditions that gather more evidence (e.g., post-market surveillance, mandatory registry entry, or restricted to specialist centers). This allows access while reducing risk of funding ineffective technology.
How do I handle equity issues in HTA?
Analyze subgroup outcomes: does the technology work equally well for different ages, genders, ethnicities, or socioeconomic groups? If benefit varies substantially, report results by subgroup and discuss equity implications. This ensures recommendations do not inadvertently increase health disparities.
Sources
- Goodman, C. S. (2004). HTA 101: Introduction to Health Technology Assessment (Version 1.0). National Library of Medicine, National Institutes of Health. link ↗
- Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., & Sculpher, M. (2013). Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ, 346, f1049. DOI: 10.1136/bmj.f1049 ↗
- Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes (4th ed.). Oxford University Press. link ↗
How to cite this page
ScholarGate. (2026, June 3). Health Technology Assessment for Evidence-Based Healthcare Decision Making. ScholarGate. https://scholargate.app/en/healthcare-management/health-technology-assessment
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Balanced Scorecard in HealthcareHealthcare Management↔ compare
- Clinical AuditHealthcare Management↔ compare
- Cost-Effectiveness Analysis in HTAHealthcare Management↔ compare
- DEA Hospital EfficiencyHealthcare Management↔ compare
- Staffing Ratio AnalysisHealthcare Management↔ compare